Compare · BIOT vs KVUE
BIOT vs KVUE
Side-by-side comparison of Instinct Bio Technical Company Holdings Inc. (BIOT) and Kenvue Inc. (KVUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOT and KVUE operate in Package Goods/Cosmetics (Consumer Discretionary), so they compete in similar markets.
- BIOT carries a market cap of $4.1M.
- KVUE has been more active in the news (38 items in the past 4 weeks vs 1 for BIOT).
- KVUE has more recent analyst coverage (25 ratings vs 0 for BIOT).
- Company
- Instinct Bio Technical Company Holdings Inc.
- Kenvue Inc.
- Price
- -
- -
- Market cap
- $4.1M
- -
- 1M return
- -
- +11.77%
- 1Y return
- -
- +14.80%
- Industry
- Package Goods/Cosmetics
- Package Goods/Cosmetics
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2023
- News (4w)
- 1
- 38
- Recent ratings
- 0
- 25
BIOT
Instinct Bio Technical Company Holdings Inc.
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) is a diversified healthcare and biotechnology company focused on developing and expanding businesses across beauty, wellness, regenerative medicine and related healthcare sectors. Through its operations and strategic partnerships, BIOT seeks to build an integrated platform connecting innovative healthcare technologies, products and services with growth opportunities across Asia and other international markets.
Latest BIOT
- SEC Form SCHEDULE 13G filed by Instinct Bio Technical Company Holdings Inc.
- SEC Form 6-K filed by Biotech Acquisition Company
- SEC Form 6-K filed by Biotech Acquisition Company
- SEC Form 6-K filed by Biotech Acquisition Company
- SEC Form 6-K filed by Biotech Acquisition Company
- INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives
- SEC Form 6-K filed by Biotech Acquisition Company
- Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
- SEC Form 6-K filed by Biotech Acquisition Company
- SEC Form 6-K filed by Biotech Acquisition Company
Latest KVUE
- FDA Approval for WOMEN'S ROGAINE issued to KENVUE BRANDS
- FDA Approval for MEN'S ROGAINE issued to KENVUE BRANDS
- FDA Approval for ROGAINE (FOR MEN) issued to KENVUE BRANDS
- FDA Approval for ROGAINE (FOR WOMEN) issued to KENVUE BRANDS
- FDA Approval for ROGAINE EXTRA STRENGTH (FOR MEN) issued to KENVUE BRANDS
- SEC Form 15-12G filed by Kenvue Inc.
- SEC Form EFFECT filed by Kenvue Inc.
- Chief Tech & Data Officer Wondrasch Michael returned 45,453 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Tillett Caroline returned 77,709 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operations Officer Stevens Meredith returned 114,183 shares to the company, closing all direct ownership in the company (SEC Form 4)